Alteri Wealth LLC Buys Shares of 1,222 Cencora, Inc. (NYSE:COR)

Alteri Wealth LLC purchased a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,222 shares of the company's stock, valued at approximately $275,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Whittier Trust Co. boosted its stake in Cencora by 0.6% in the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after purchasing an additional 44 shares during the period. Shepherd Financial Partners LLC lifted its position in shares of Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock worth $1,223,000 after buying an additional 46 shares during the last quarter. WASHINGTON TRUST Co grew its holdings in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the last quarter. JFS Wealth Advisors LLC boosted its holdings in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its holdings in Cencora by 1.1% in the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock valued at $1,003,000 after buying an additional 47 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the transaction, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock worth $13,580,967 over the last quarter. 10.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

COR has been the subject of several recent research reports. Bank of America increased their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. UBS Group upped their price target on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Finally, Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $290.00.

Cencora Price Performance

COR traded up $13.23 during trading on Wednesday, reaching $304.04. The stock had a trading volume of 2,384,298 shares, compared to its average volume of 1,509,714. The stock has a market cap of $58.96 billion, a PE ratio of 43.25, a PEG ratio of 1.31 and a beta of 0.60. The business has a 50-day moving average of $274.32 and a 200-day moving average of $252.29. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a one year low of $214.77 and a one year high of $308.93.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter in the previous year, the company posted $3.80 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.